USD
$0.00
(0.00%
)At Close (As of Sep 26, 2025)
$632.12M
Market Cap
-
P/E Ratio
-0.61
EPS
$3.60
52 Week High
$0.66
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $115M |
Total Revenue | $115M |
Cost Of Revenue | $4.2M |
Costof Goods And Services Sold | $4.2M |
Operating Income | -$60M |
Selling General And Administrative | $36M |
Research And Development | $138M |
Operating Expenses | $175M |
Investment Income Net | - |
Net Interest Income | -$9.7M |
Interest Income | $1.8M |
Interest Expense | $12M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $4.2M |
Income Before Tax | -$56M |
Income Tax Expense | $893K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$57M |
Comprehensive Income Net Of Tax | - |
Ebit | -$44M |
Ebitda | -$40M |
Net Income | -$57M |
Field | Value (USD) |
---|---|
Total Assets | $315M |
Total Current Assets | $310M |
Cash And Cash Equivalents At Carrying Value | $46M |
Cash And Short Term Investments | $46M |
Inventory | - |
Current Net Receivables | $5.3M |
Total Non Current Assets | $5.4M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $248M |
Other Current Assets | $10M |
Other Non Current Assets | - |
Total Liabilities | $286M |
Total Current Liabilities | $45M |
Current Accounts Payable | $2.3M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $961K |
Total Non Current Liabilities | $241M |
Capital Lease Obligations | $5.4M |
Long Term Debt | $198M |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $203M |
Other Current Liabilities | $55M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $29M |
Treasury Stock | - |
Retained Earnings | -$1.3B |
Common Stock | $23K |
Common Stock Shares Outstanding | $226M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$3.5M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $4.2M |
Capital Expenditures | $0 |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | $29M |
Cashflow From Financing | -$11M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | $629K |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$57M |
Field | Value (USD) |
---|---|
Gross Profit | $115M |
Total Revenue | $115M |
Cost Of Revenue | $4.2M |
Costof Goods And Services Sold | $4.2M |
Operating Income | -$60M |
Selling General And Administrative | $36M |
Research And Development | $138M |
Operating Expenses | $175M |
Investment Income Net | - |
Net Interest Income | -$9.7M |
Interest Income | $1.8M |
Interest Expense | $12M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $4.2M |
Income Before Tax | -$56M |
Income Tax Expense | $893K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$57M |
Comprehensive Income Net Of Tax | - |
Ebit | -$44M |
Ebitda | -$40M |
Net Income | -$57M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to the discovery, development, and commercialization of innovative therapies targeting immunology, inflammation, and oncology. With a strong focus on addressing unmet medical needs, Gossamer Bio is advancing a diverse pipeline of drug candidates that leverage cutting-edge scientific insights. As the company moves forward in its clinical programs, it aims to deliver transformative treatment options for patients suffering from complex diseases, positioning itself as a key player in the evolving biopharmaceutical landscape.